Abstract
Abstract
 Elevated plasma lipoprotein (A) concentration is considered as a predisposing risk factor for cardiovascular disease and in-stent restenosis. Lipoprotein (A) is a lipoprotein with an LDL-like particle that contains Apo-lipoprotein B100 and is associated with cardiovascular complications. The most prevalent complication associated with percutaneous coronary intervention is in-stent restenosis.In-stent Restenosis affected 40% of all angioplasties in the pre-stent era, then 28% in the (BMS) era. Furthermore, the introduction of (DES) second generation and drug-coated balloons has further reduced restenosis rates to less than 10%. The aim of this review paper is to investigate the clinical association of Lipoprotein (A) concentration in the occurrence of in-stent restenosis. Our paper possesses some limitations Firstly, it does not explain how lipoprotein concentrations are established. Secondly, the mechanism underlying the lipoprotein (A) lowering effect of current therapy.
 Keywords: Lipoprotein A, in-stent restenosis, predisposing factor, Diabetes mellitus, Cardio-vascular disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
